First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Exelixis: the story is balanced — Cabozantinib US net product revenue growth and market share trends in RCC/HCC - particularly penetration in first-line…
★ Analysts see FY2027 revenue reaching $2.6B — +12.0% growth in a single year.
What Moves the Stock
1Cabozantinib US net product revenue growth and market share trends in RCC/HCC - particularly penetration in first-line HCC and combination therapy adoption
2Clinical trial readouts for pipeline assets (zanzalintinib in biliary tract cancer, XL092 in solid tumors) and label expansion opportunities for cabozantinib
3Collaboration revenue volatility from partner milestone achievements and ex-US sales performance (Ipsen European sales trends)
4Capital allocation decisions including share repurchase authorization utilization and potential business development activity
5Competitive dynamics in RCC/HCC including CheckMate-9ER uptake, TKI/IO combination data, and emerging targeted therapies
6Cabozantinib net product revenue in US (estimated 65-70% of total) - renal cell carcinoma and hepatocellular carcinoma indications
7Collaboration revenue from Ipsen (ex-US cabozantinib rights) and Takeda (Japan rights) - royalties and milestones (estimated 25-30%)
8Other product revenue and contract services (estimated 5%)
growth - Attracts growth-oriented investors seeking exposure to commercial-stage biotech with established revenue base…
Rising rates create modest headwinds through higher discount rates applied to future pipeline value…
Watch on earnings: Cabozantinib US quarterly net product revenue and year-over-year growth rates, New patient starts and total prescriptions (TRx) data from IQVIA or Symphony Health, Ipsen ex-US cabozantinib sales reported in quarterly earnings (proxy for international demand).
One Sentence Summary:
Exelixis: the story is balanced — cabozantinib us net product revenue growth and market share trends in rcc/hcc - particularly penetration in first-line hcc and combination.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.